Review



dream  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology dream
    A20 mRNA Therapy Suppressed the Expression of <t>DREAM,</t> a Known A20 Inhibitory Molecule, and <t>Reduced</t> <t>SMAD2,</t> αSMA, and Procollagen in Systemic Sclerosis Skin Tissue and Human Skin Fibroblasts. (A) Skin and lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. The number of antibody-positive cells (mean ± SEM) is plotted. Original magnification: 400×; scale bar: 100 μm. (B) The protein levels of DREAM and SMAD2 were measured in cells treated with TGF-β (20 ng/mL) for 48 h GAPDH served as the validation control. For quantification, three fields per mouse were analyzed (n = 5 mice per group). Data are presented as mean ± SD from a representative experiment of three independent experiments. Statistical significance was determined by one-way ANOVA (A, B) . (*P < 0.05; **P < 0.01).
    Dream, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 32 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dream/product/Santa Cruz Biotechnology
    Average 93 stars, based on 32 article reviews
    dream - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects"

    Article Title: A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2025.1665998

    A20 mRNA Therapy Suppressed the Expression of DREAM, a Known A20 Inhibitory Molecule, and Reduced SMAD2, αSMA, and Procollagen in Systemic Sclerosis Skin Tissue and Human Skin Fibroblasts. (A) Skin and lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. The number of antibody-positive cells (mean ± SEM) is plotted. Original magnification: 400×; scale bar: 100 μm. (B) The protein levels of DREAM and SMAD2 were measured in cells treated with TGF-β (20 ng/mL) for 48 h GAPDH served as the validation control. For quantification, three fields per mouse were analyzed (n = 5 mice per group). Data are presented as mean ± SD from a representative experiment of three independent experiments. Statistical significance was determined by one-way ANOVA (A, B) . (*P < 0.05; **P < 0.01).
    Figure Legend Snippet: A20 mRNA Therapy Suppressed the Expression of DREAM, a Known A20 Inhibitory Molecule, and Reduced SMAD2, αSMA, and Procollagen in Systemic Sclerosis Skin Tissue and Human Skin Fibroblasts. (A) Skin and lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. The number of antibody-positive cells (mean ± SEM) is plotted. Original magnification: 400×; scale bar: 100 μm. (B) The protein levels of DREAM and SMAD2 were measured in cells treated with TGF-β (20 ng/mL) for 48 h GAPDH served as the validation control. For quantification, three fields per mouse were analyzed (n = 5 mice per group). Data are presented as mean ± SD from a representative experiment of three independent experiments. Statistical significance was determined by one-way ANOVA (A, B) . (*P < 0.05; **P < 0.01).

    Techniques Used: Expressing, Staining, Biomarker Discovery, Control

    A20 mRNA Therapy Reduces Fibrosis in Systemic Sclerosis Lung Tissue by Inhibiting DREAM Expression. Lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. For quantification, three fields per mouse were analyzed (n = 5 mice per group), and the number of antibody-positive cells is plotted as mean ± SEM. Original magnification: 400×; scale bar: 100 μm. Bar graph shows data from one representative experiment (**P < 0.01). The statistical significance of all graphs was determined by one-way ANOVA (A) . The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/bAoEK8 .
    Figure Legend Snippet: A20 mRNA Therapy Reduces Fibrosis in Systemic Sclerosis Lung Tissue by Inhibiting DREAM Expression. Lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. For quantification, three fields per mouse were analyzed (n = 5 mice per group), and the number of antibody-positive cells is plotted as mean ± SEM. Original magnification: 400×; scale bar: 100 μm. Bar graph shows data from one representative experiment (**P < 0.01). The statistical significance of all graphs was determined by one-way ANOVA (A) . The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/bAoEK8 .

    Techniques Used: Expressing, Staining

    Proposed mechanism by which A20 mRNA therapy attenuates fibrosis in systemic sclerosis. In the systemic sclerosis condition (left), activation of TLR4 initiates TRAF6-mediated NF-κB signaling and upregulates TGF-β, IL-8, collagen type I (Col1), and α-smooth muscle actin (α-SMA), thereby promoting fibroblast activation and extracellular matrix (ECM) accumulation. In contrast, A20 mRNA encapsulated in lipid nanoparticles (LNPs) (right) restores A20 protein expression, leading to inhibition of TRAF6-dependent NF-κB phosphorylation, suppression of DREAM and SMAD pathways, and subsequent reduction of fibrotic markers in skin and lung fibroblasts. Downward arrows indicate decreased expression following A20 mRNA treatment. The schematic was created with BioRender.com .
    Figure Legend Snippet: Proposed mechanism by which A20 mRNA therapy attenuates fibrosis in systemic sclerosis. In the systemic sclerosis condition (left), activation of TLR4 initiates TRAF6-mediated NF-κB signaling and upregulates TGF-β, IL-8, collagen type I (Col1), and α-smooth muscle actin (α-SMA), thereby promoting fibroblast activation and extracellular matrix (ECM) accumulation. In contrast, A20 mRNA encapsulated in lipid nanoparticles (LNPs) (right) restores A20 protein expression, leading to inhibition of TRAF6-dependent NF-κB phosphorylation, suppression of DREAM and SMAD pathways, and subsequent reduction of fibrotic markers in skin and lung fibroblasts. Downward arrows indicate decreased expression following A20 mRNA treatment. The schematic was created with BioRender.com .

    Techniques Used: Activation Assay, Expressing, Inhibition, Phospho-proteomics



    Similar Products

    dream taq dna polymerase  (Thermo Fisher)
    99
    Thermo Fisher dream taq dna polymerase
    Dream Taq Dna Polymerase, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dream taq dna polymerase/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    dream taq dna polymerase - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    sirolimus eluting resorbable magnesium scaffold system (dreams 3g rms  (Biotronik GmbH)
    90
    Biotronik GmbH sirolimus eluting resorbable magnesium scaffold system (dreams 3g rms
    Sirolimus Eluting Resorbable Magnesium Scaffold System (Dreams 3g Rms, supplied by Biotronik GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sirolimus eluting resorbable magnesium scaffold system (dreams 3g rms/product/Biotronik GmbH
    Average 90 stars, based on 1 article reviews
    sirolimus eluting resorbable magnesium scaffold system (dreams 3g rms - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    dream taq dna polymerase kit  (Fisher Scientific)
    86
    Fisher Scientific dream taq dna polymerase kit
    Dream Taq Dna Polymerase Kit, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dream taq dna polymerase kit/product/Fisher Scientific
    Average 86 stars, based on 1 article reviews
    dream taq dna polymerase kit - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    dream taq dna polymerase kit  (Thermo Fisher)
    99
    Thermo Fisher dream taq dna polymerase kit
    Dream Taq Dna Polymerase Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dream taq dna polymerase kit/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    dream taq dna polymerase kit - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    pcr reaction dream taq dna polymerase  (Thermo Fisher)
    99
    Thermo Fisher pcr reaction dream taq dna polymerase
    Pcr Reaction Dream Taq Dna Polymerase, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pcr reaction dream taq dna polymerase/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    pcr reaction dream taq dna polymerase - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    dream  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology dream
    A20 mRNA Therapy Suppressed the Expression of <t>DREAM,</t> a Known A20 Inhibitory Molecule, and <t>Reduced</t> <t>SMAD2,</t> αSMA, and Procollagen in Systemic Sclerosis Skin Tissue and Human Skin Fibroblasts. (A) Skin and lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. The number of antibody-positive cells (mean ± SEM) is plotted. Original magnification: 400×; scale bar: 100 μm. (B) The protein levels of DREAM and SMAD2 were measured in cells treated with TGF-β (20 ng/mL) for 48 h GAPDH served as the validation control. For quantification, three fields per mouse were analyzed (n = 5 mice per group). Data are presented as mean ± SD from a representative experiment of three independent experiments. Statistical significance was determined by one-way ANOVA (A, B) . (*P < 0.05; **P < 0.01).
    Dream, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dream/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    dream - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A20 mRNA Therapy Suppressed the Expression of DREAM, a Known A20 Inhibitory Molecule, and Reduced SMAD2, αSMA, and Procollagen in Systemic Sclerosis Skin Tissue and Human Skin Fibroblasts. (A) Skin and lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. The number of antibody-positive cells (mean ± SEM) is plotted. Original magnification: 400×; scale bar: 100 μm. (B) The protein levels of DREAM and SMAD2 were measured in cells treated with TGF-β (20 ng/mL) for 48 h GAPDH served as the validation control. For quantification, three fields per mouse were analyzed (n = 5 mice per group). Data are presented as mean ± SD from a representative experiment of three independent experiments. Statistical significance was determined by one-way ANOVA (A, B) . (*P < 0.05; **P < 0.01).

    Journal: Frontiers in Immunology

    Article Title: A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects

    doi: 10.3389/fimmu.2025.1665998

    Figure Lengend Snippet: A20 mRNA Therapy Suppressed the Expression of DREAM, a Known A20 Inhibitory Molecule, and Reduced SMAD2, αSMA, and Procollagen in Systemic Sclerosis Skin Tissue and Human Skin Fibroblasts. (A) Skin and lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. The number of antibody-positive cells (mean ± SEM) is plotted. Original magnification: 400×; scale bar: 100 μm. (B) The protein levels of DREAM and SMAD2 were measured in cells treated with TGF-β (20 ng/mL) for 48 h GAPDH served as the validation control. For quantification, three fields per mouse were analyzed (n = 5 mice per group). Data are presented as mean ± SD from a representative experiment of three independent experiments. Statistical significance was determined by one-way ANOVA (A, B) . (*P < 0.05; **P < 0.01).

    Article Snippet: Antibodies targeting A20 (ab13597, Abcam, Cambridge, UK), TRAF6 (SC-8409, Santa Cruz Technologies, Santa Cruz, CA, USA), NF-κB (ab16502, Abcam), DREAM (SC-166916, Santa Cruz Technologies), SMAD2 (ab33875, Abcam), Col1a1 (PA5-29569, Invitrogen, CA, USA) αSMA (ab7817, Abcam), c-Myc (SC-40, Santa Cruz), p53 (SC-6243, Santa Cruz) and GAPDH (ab181602, Abcam) were used to measure the corresponding protein levels by Western blotting (SNAP i.d.

    Techniques: Expressing, Staining, Biomarker Discovery, Control

    A20 mRNA Therapy Reduces Fibrosis in Systemic Sclerosis Lung Tissue by Inhibiting DREAM Expression. Lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. For quantification, three fields per mouse were analyzed (n = 5 mice per group), and the number of antibody-positive cells is plotted as mean ± SEM. Original magnification: 400×; scale bar: 100 μm. Bar graph shows data from one representative experiment (**P < 0.01). The statistical significance of all graphs was determined by one-way ANOVA (A) . The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/bAoEK8 .

    Journal: Frontiers in Immunology

    Article Title: A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects

    doi: 10.3389/fimmu.2025.1665998

    Figure Lengend Snippet: A20 mRNA Therapy Reduces Fibrosis in Systemic Sclerosis Lung Tissue by Inhibiting DREAM Expression. Lung sections were stained with antibodies against DREAM, SMAD2, procollagen, and αSMA. For quantification, three fields per mouse were analyzed (n = 5 mice per group), and the number of antibody-positive cells is plotted as mean ± SEM. Original magnification: 400×; scale bar: 100 μm. Bar graph shows data from one representative experiment (**P < 0.01). The statistical significance of all graphs was determined by one-way ANOVA (A) . The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/bAoEK8 .

    Article Snippet: Antibodies targeting A20 (ab13597, Abcam, Cambridge, UK), TRAF6 (SC-8409, Santa Cruz Technologies, Santa Cruz, CA, USA), NF-κB (ab16502, Abcam), DREAM (SC-166916, Santa Cruz Technologies), SMAD2 (ab33875, Abcam), Col1a1 (PA5-29569, Invitrogen, CA, USA) αSMA (ab7817, Abcam), c-Myc (SC-40, Santa Cruz), p53 (SC-6243, Santa Cruz) and GAPDH (ab181602, Abcam) were used to measure the corresponding protein levels by Western blotting (SNAP i.d.

    Techniques: Expressing, Staining

    Proposed mechanism by which A20 mRNA therapy attenuates fibrosis in systemic sclerosis. In the systemic sclerosis condition (left), activation of TLR4 initiates TRAF6-mediated NF-κB signaling and upregulates TGF-β, IL-8, collagen type I (Col1), and α-smooth muscle actin (α-SMA), thereby promoting fibroblast activation and extracellular matrix (ECM) accumulation. In contrast, A20 mRNA encapsulated in lipid nanoparticles (LNPs) (right) restores A20 protein expression, leading to inhibition of TRAF6-dependent NF-κB phosphorylation, suppression of DREAM and SMAD pathways, and subsequent reduction of fibrotic markers in skin and lung fibroblasts. Downward arrows indicate decreased expression following A20 mRNA treatment. The schematic was created with BioRender.com .

    Journal: Frontiers in Immunology

    Article Title: A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects

    doi: 10.3389/fimmu.2025.1665998

    Figure Lengend Snippet: Proposed mechanism by which A20 mRNA therapy attenuates fibrosis in systemic sclerosis. In the systemic sclerosis condition (left), activation of TLR4 initiates TRAF6-mediated NF-κB signaling and upregulates TGF-β, IL-8, collagen type I (Col1), and α-smooth muscle actin (α-SMA), thereby promoting fibroblast activation and extracellular matrix (ECM) accumulation. In contrast, A20 mRNA encapsulated in lipid nanoparticles (LNPs) (right) restores A20 protein expression, leading to inhibition of TRAF6-dependent NF-κB phosphorylation, suppression of DREAM and SMAD pathways, and subsequent reduction of fibrotic markers in skin and lung fibroblasts. Downward arrows indicate decreased expression following A20 mRNA treatment. The schematic was created with BioRender.com .

    Article Snippet: Antibodies targeting A20 (ab13597, Abcam, Cambridge, UK), TRAF6 (SC-8409, Santa Cruz Technologies, Santa Cruz, CA, USA), NF-κB (ab16502, Abcam), DREAM (SC-166916, Santa Cruz Technologies), SMAD2 (ab33875, Abcam), Col1a1 (PA5-29569, Invitrogen, CA, USA) αSMA (ab7817, Abcam), c-Myc (SC-40, Santa Cruz), p53 (SC-6243, Santa Cruz) and GAPDH (ab181602, Abcam) were used to measure the corresponding protein levels by Western blotting (SNAP i.d.

    Techniques: Activation Assay, Expressing, Inhibition, Phospho-proteomics